Last reviewed · How we verify
R-combination chemotherapy
R-combination chemotherapy uses rituximab (a monoclonal antibody targeting CD20) combined with cytotoxic chemotherapy agents to kill B-cell malignancies.
R-combination chemotherapy uses rituximab (a monoclonal antibody targeting CD20) combined with cytotoxic chemotherapy agents to kill B-cell malignancies. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma.
At a glance
| Generic name | R-combination chemotherapy |
|---|---|
| Sponsor | Shandong Provincial Hospital |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. The combination with chemotherapy agents (typically cyclophosphamide, doxorubicin, vincristine, and prednisone in R-CHOP regimens) provides synergistic cytotoxic effects against lymphoid malignancies. This approach enhances tumor cell death through both immunological and chemotherapeutic mechanisms.
Approved indications
- B-cell non-Hodgkin lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infusion reactions
- Nausea/vomiting
- Infection
- Mucositis
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-combination chemotherapy CI brief — competitive landscape report
- R-combination chemotherapy updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI